Adult: PO Acute bronchospasm 2-4 mg (up to 8 mg) 3-4 times/day. Extended release 8 mg twice daily. Children 2 – 6 years: 2.5 ml syrup, 3-4 times daily 6-12 years: 5 ml syrup, 3-4 times daily Over 12 years: 5-10 ml syrup, 3-4 times daily (2-4 mg tablet, 3-4 times daily) Inhalation Capsule: Adults: For the relief of acute asthma or before exercise 400 µg (2 ConviCaps). The recommended dose for maintenance treatment or prophylactic therapy is 400 µg (2 ConviCaps) three to four times a day. Maximum dose is 1600 µg/day. Children: In the treatment of episodic asthma or before exercise 200 µg (1 ConviCap). The recommended dose for maintenance treatment or prophylactic treatment is 200 µg (1 ConviCap) three to four times a day. Maximum dose is 800 µg/day. As aerosol: Inhalation Acute bronchospasm 100 or 200 mcg 3-4 times/day. 2 puffs may be given prior to exertion to prevent exercise-induced bronchospasm. Acute severe asthma As MDI: 4-6 inhalations every 10-20 mins. Severe bronchospasm Via nebuliser: 2.5-5 mg up to 4 times/day. Children For relief of acute bronchospasm in the maintenance of episodic asthma or before exercise: one 1 puff may be administered as a single dose. For routine maintenance and prophylaxis therapy: one 1 puff three or four times daily, increasing if necessary to two puffs three or four times daily. Elderly The dosage is the same as that for adults. Nebuliser Solution Nebuliser Solution is for inhalation use only, to be breathed in through the mouth, under the direction of a physician, using a suitable nebuliser. The solution should not be injected or swallowed. Adults (including the elderly): 2.5 mg to 5 mg salbutamol up to four times a day. Up to 40 mg per day can be given under strict medical supervision in hospital. Children 4 years and above: 2.5 mg to 5 mg up to four times a day. Children 18 months to 4 years: 2.5 mg up to four times a day.The dose may be increased to 5 mg if necessary. Infants under 18 months old: 1.25 mg (0.25 mg/kg) to 2.5 mg up to four times a day. Respirator Solution By Intermittent Administration : Adult : Respirator Solution 0.5-1.0 ml should be diluted to final volume of 2.0-4.0 ml with normal saline for injection. The resulting solution is inhaled from a suitably driven nebulizer until aerosol generation ceases. Should take about 10 minutes. Respirator Solution may be used undiluted for intermittent administration. For this 2.0 ml of the solution is placed in the nebulizer and the patient allowed to inhale until bronchodilatation is achieved. This usually takes 3-5 minutes. Children under 12 years age: 0.5 ml of the solution diluted to 2.0-4.0 ml with normal saline. Intermittent treatment may be repeated four times a day. By Continuous Administration : Respirator Solution is diluted with normal saline for injection, 1-2 ml solution made upto 100 ml with diluent. The diluted solution is administered as an aerosol by a suitably driven nebulizer. The usual rate of administration is 1-2 mg/hour.

Contraindication ::

Salbuatmol inhaler is contraindicated in patients with a history of hypersensitivity to any of its components. Although intravenous Salbutamol, and occasionally Salbutamol tablets, is used in the management of premature labour uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage or toxaemia of pregnancy, Salbutamol inhaler preparations are not appropriate for managing premature labour. Salbutamol preparation should not be used for threatened abortion during the first or second trimesters of pregnancy.

Drug Precautions ::

Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. In the event of previously effective dose of Salbuatmol inhaler failing to give relief for at least three hours, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken.

Salbutamol is a direct-acting sympathomimetic with beta-adrenergic activity and selective action on ?2 receptors, producing bronchodilating effects. It also decreases uterine contractility.

Drug Interactions ::

Diuretics, corticosteroids and xanthines may augment hypokalaemia. CV effects potentiated by MAOIs, TCAs, sympathomimetics. Increases absorption of sulfamethoxazole when used together. May markedly increase heart rate and BP when used with atomoxetine. Reduces serum levels of digoxin. Hypokalaemia induced by salbutamol increases the risk of digitalis toxicity. BP should be closely monitored if linezolid is used concurrently with salbutamol.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.